

Michael N. Dohn

Mailing Address: Apartado 509, San Pedro de Macorís, SPM 21000, República Dominicana

US Mailing Address: SAMS, PO Box 399, Ambridge, PA 15003 USA

E-mail: dohnfamily@sams-usa.org **Mobile:** +1 (809) 357-5155 **Office:** +1 (809) 526-7731

Date of Birth: 2 January 1953 (Middletown, Ohio, USA) **Citizenship:** USA

Languages: English and Spanish **Current residency:** Dominican Republic

Website: www.dohnfamily.org

PROFESSIONAL POSITIONS

- 1999 - Present Society of Anglican Missionaries and Senders (SAMS)
1013 Merchant Street, Ambridge, PA 15003 USA
Missionary: Clínica Esperanza y Caridad (Iglesia Episcopal Dominicana)
C/ Sánchez # 9, Miramar, San Pedro de Macorís, República Dominicana
- Administrator, Human Ethics Review Committee: 2010 – Present
 - Community Health Project Manager: 2004 – Present
 - Medical Director: 2004 – 2013
- 1996 - 1999 Schulman Associates Institutional Review Board
and Cincinnati, OH 45242 USA
2003 - 2004
- Full Board Member: 1996 – 1999
 - Alternate Board Member: 2003 – 2004
- 1996 - 1999 Infectious Diseases Division, Department of Internal Medicine
University of Cincinnati College of Medicine
Cincinnati, OH 45267-0560 USA
- Associate Professor of Clinical Medicine: 1998 – 1999
 - Assistant Professor of Clinical Medicine: 1996 – 1998
- 1989 - 1999 Infectious Diseases Center / AIDS Treatment Center
University of Cincinnati Medical Center
- Deputy Director for Clinical Care: 1997 – 1999
 - Attending Physician: 1989 – 1996
- 1989 - 1996 Pulmonary Medicine & Intensive Care Division, Dept. of Internal Medicine
University of Cincinnati College of Medicine
- Assistant Professor of Clinical Medicine
- 1984 - 1989 Private Medical Practice
Pulmonary Medicine and Intensive Care
Medical Associates of Cincinnati, Inc., Cincinnati, OH USA
- 1984 - 1989 Associate Director, Pulmonary Medicine and Intensive Care
The Jewish Hospital of Cincinnati, Cincinnati, OH USA

EDUCATION

- Sep 2008 - Nov 2012 London School of Hygiene and Tropical Medicine
University of London International Programme
London WC1B 5DN, United Kingdom
Project Report ~ Sharing medicines: metaphoric & metonymic associations
of pharmaceuticals, Dominican Republic
Adviser: Hugo Pilkington PhD (Université Paris 8, Paris, France)
MSc Public Health (Health Promotion stream): 1 November 2012
- Jul 1982 - Jun 1984 Fellow, Division of Pulmonary Medicine and Intensive Care
University of Cincinnati College of Medicine
Cincinnati, OH USA
- Jul 1979 - Jun 1982 Resident, Internal Medicine
The Jewish Hospital of Cincinnati
Cincinnati, OH USA
- Sep 1975 - Jun 1979 University of Cincinnati College of Medicine
231 Bethesda Avenue, Cincinnati, OH 45229 USA
Doctor of Medicine: 10 June 1979
- Jul 1971 - Jun 1975 Miami University (English major)
Oxford, Ohio USA

MEDICAL LICENSURE

Ohio	35-04-5531-D	October 1980 to present
Kentucky	21151	January 1981 to present
Indiana	01030520	March 1981 to June 1989

CERTIFICATIONS

National Board of Medical Examiners	No. 212814 – 1 July 1980
American Board of Internal Medicine	No. 085085 – 14 September 1983

OTHER PROFESSIONAL CERTIFICATIONS

- Certificate in Teaching English as a Foreign Language (June 2008)
Bridge TEFL, Denver, CO 80246 USA
- Divemaster (December 2009, Professional Association of Dive Instructors)
PADI Americas, 30151 Tomas, Rancho Santa Margarita, CA 92688 USA
PADI Professional Certificate No. 264 557 (Currently active and insured)

ARTICLES (Investigator initiated)

1. Dohn MN, Dohn AL, Montgomery LM. Medicine sharing, efficacy, and adverse events associated with medicines distributed by short-term medical mission teams: a qualitative study in the Dominican Republic. PLoS one. Under review.

2. Dohn MN, Pilkington H. Sharing medicine: qualitative study of the candidacy of medicines and other household items for sharing, Dominican Republic. PLoS One. Under review.
3. Dohn MN, Jiménez SA, Nolasco Pozo M, Cabrera EA, Dohn AL. Alcohol use and church attendance among seventh through twelfth grade students, Dominican Republic, 2011. J Relig Health 2012; 51(4). DOI: 10.1007/s10943-012-9663-0 [published online 21 Nov 2012].
4. Dohn MN, Dohn AL. Short-term medical mission teams: What they do well . . . and not so well [opinion]. Evangelical Missions Quarterly 2006; 42(2):216-222.
5. Dohn AL, Chávez A, Dohn MN, Saturria L, Pimental C. Changes in Health Indicators in Three Dominican Communities Related to Health and Microcredit Programs. Rev Panam Salud Pública / Pan Am J Public Health 2004; 15(3):185-193.
6. Dohn MN, Dohn AL. Quality of Care on Short-term Medical Missions: Experience with a standardized patient record and related issues. Missiology: An International Review 2003; 31(4): 417-429.
7. Rosenberg DM, McCarthy W, Slavinsky J, Chan CK, Montaner J, Braun J, Dohn MN, Caldwell PT. Atovaquone suspension for treatment of *Pneumocystis carinii* pneumonia in HIV-infected patients. AIDS 2001; 15(2):211-214.
8. Dohn MN, White ML, Vigdorth EM, Buncher CR, Hertzberg VS, Baughman RP, Smulian AG, Walzer PD. Geographic clustering of *Pneumocystis carinii* pneumonia in patients with HIV infection. Am J Resp Crit Care Med 2000; 162:1617-1621.
9. Para MF, Finkelstein D, Becker S, Dohn MN, Walawander A, Black JR. Reduced toxicity with gradual initiation of trimethoprim-sulfamethoxazole as primary prophylaxis for *Pneumocystis carinii* pneumonia: AIDS Clinical Trials Group 268. J Acquir Immune Defic Syndr 2000; 24:337-343.
10. Chan C, Montaner J, Lefebvre EA, Morey G, Dohn MN, McIvor RA, Scott J, Marina R, Caldwell P. Atovaquone suspension compared with aerosolized pentamidine for prevention of *Pneumocystis carinii* pneumonia in human immunodeficiency virus-infected subjects intolerant of trimethoprim or sulfonamides. J Infect Dis 1999; 180:369-376.
11. Walker DJ, Wakefield AE, Dohn MN, Miller RF, Baughman RP, Hossler PA, Bartlett MS, Smith JW, Kazanjian P, Grant J, Mechnick SR. Sequence polymorphisms in the *Pneumocystis carinii* cytochrome B gene and their associations with atovaquone prophylaxis failure. J Infect Dis 1998; 178(6):1767-1775.
12. Keely SP, Baughman RP, Smulian AG, Dohn MN, Stringer JR. Source of *Pneumocystis carinii* in recurrent episodes of pneumonia in AIDS patients. AIDS 1996; 10(8):881-888.

13. Zarkin GA, Bala MV, Wood LL, Bennett CL, Simpson K, Dohn MN. Estimating the cost-effectiveness of atovaquone versus pentamidine in the treatment of mild-to-moderate *Pneumocystis carinii* pneumonia. *PharmacoEconomics* 1996; 9:525-534.
14. Hayner CE, Baughman RP, Linnemann CC, Dohn MN. Relationship between cytomegalovirus retrieved by bronchoalveolar lavage and mortality in patients with HIV. *Chest* 1995; 107:735-740.
15. Baughman RP, Dohn MN, Frame PT. Continuing utility of bronchoalveolar lavage to diagnose opportunistic infections in AIDS patients. *Amer J Med* 1994; 97:515-522.
16. Smulian AG, Linke MJ, Cushion MT, Baughman RP, Frame PT, Dohn MN, White ML, Walzer PD. Analysis of *Pneumocystis carinii* organism burden, viability and antigens in bronchoalveolar lavage fluid (BALF) in patients with pneumocystosis: correlation with disease severity. *AIDS* 1994; 8:1555-1562.
17. Dohn MN, Weinberg WG, Torres RA, Follansbee SE, Caldwell PT, Scott J, Gathe J Jr, Haghighat DP, Sampson JH, Spotkov J, Deresinski S, Meyer RD, Lancaster D, and the Atovaquone Study Group. Oral atovaquone compared with intravenous pentamidine for *Pneumocystis carinii* pneumonia in patients with AIDS. *Ann Intern Med* 1994; 121:174-180.
18. Connolly MG Jr, Baughman RP, Dohn MN, Linnemann CC Jr. Recovery of viruses other than cytomegalovirus from bronchoalveolar lavage fluid. *Chest* 1994; 105:1775-1781.
19. O'Riordan TG, Baughman RP, Dohn M, Smaldone GC. Lobar pentamidine levels and *Pneumocystis carinii* pneumonia following aerosolized pentamidine. *Chest* 1994; 105:53-56.
20. Connolly MG Jr, Baughman RP, Dohn MN. *Mycobacterium kansasii* presenting as an endobronchial lesion. *Am Rev Respir Dis* 1993; 148:1405-1407.
21. Sternberg RI, Baughman RP, Dohn MN, First MN. Utility of bronchoalveolar lavage in assessing pneumonia in immunosuppressed renal transplant patients. *Am J Med* 1993; 95:358-364.
22. Baughman RP, Dohn MN, Shipley R, Buchsbaum JA, Frame PT. Increased *Pneumocystis carinii* recovery from the upper lobes in pneumocystis pneumonia: the effect of aerosol pentamidine prophylaxis. *Chest* 1993; 103:426-432.
23. Dohn MN, Baughman RP, Vigdorth EM, Frame DL. Equal survival rates for first, second, and third episodes of *Pneumocystis carinii* pneumonia in AIDS patients. *Arch Intern Med* 1992; 152:2465-2470.
24. Baughman RP, Rhodes JC, Dohn MN, Henderson H, Frame PT. Detection of cryptococcal antigen in bronchoalveolar lavage fluid: a prospective study of diagnostic utility. *Am Rev Respir Dis* 1992; 145:1226-1229.

25. Dohn MN, Frame PT, Baughman RP, LaFon SW, Smulian AG, Caldwell P, Rogers MD. Open label efficacy and safety trial of 42 days of 566C80 for *Pneumocystis carinii* pneumonia in AIDS patients. *J Protozool* 1991; 38:220S-221S.
26. Baughman RP, Dohn MN, Frame PT. Generalized immune response to *Pneumocystis carinii* infection in the lung. *J Protozool* 1991; 38:187S-188S.
27. Falloon J, Kovacs J, Hughes W, O'Neill D, Polis M, Davey R, Rogers M, LaFon S, Feuerstein I, Lancaster D, Land M, Tuazon C, Dohn M, Greenberg S, Lane HC, Masur H. 566C80, a hydroxynaphthoquinone, for the treatment of *Pneumocystis pneumonia* in patients with the acquired immunodeficiency syndrome. *N Engl J Med* 1991; 325:1534-1538.
28. Colangelo G, Baughman RP, Dohn MN, Frame PT. Follow-up bronchoalveolar lavage in AIDS patients with *Pneumocystis carinii* pneumonia: *Pneumocystis carinii* burden predicts early relapse. *Am Rev Respir Dis* 1991; 143:1067-1071.
29. Baughman RP, Dohn MN, Loudon RG, Frame PT. Bronchoscopy with bronchoalveolar lavage in tuberculosis and fungal infections. *Chest* 1991; 99:92-97.
30. Javaheri S, Bosken CH, Lim SP, Dohn MN, Greene NB, Baughman RP. Effects of hypohydration on lung functions in humans. *Am Rev Respir Dis* 1987; 135:597-599.
31. Dohn MN, Baughman RP. Effect of changing instilled volume for bronchoalveolar lavage in patients with interstitial lung disease. *Am Rev Respir Dis* 1985; 132:390-92.
32. Baughman RP, Strohofer S, Dohn MN. Decreased phosphatidylcholine in the lung fluid of patients with sarcoidosis. *Lipids* 1985; 20(7):496-99.
33. Baughman RP, Solinger A, Hurtubise P, Dohn MN, Walzer MN, Rashkin MC, Dorn D. Bronchoalveolar lavage in patients with the acquired immune deficiency syndrome (AIDS). *AIDS Research* 1984; 1(2):91-97.

BOOK CHAPTERS

1. Dohn MN, Dohn AL. Short-term medical teams: What they do well . . . and not so well. In: Fortunak LA, Moreau AS (eds). *Engaging the Church: Analyzing the Canvas of Short-term Missions*. 2008. Wheaton, IL: Evangelism and Missions Information Services (Wheaton College).
2. Dohn MN, Frame PT. Chapter 22: Protozoan Infections. In: Powderly WG (ed). *Manual of HIV Therapeutics*. A Little Brown Lippincott-Raven Spiral[®] Manual. Philadelphia, PA: Lippincott-Raven Publishers. 1997.

3. Frame PT, Dohn MN. Preventative Interventions for Persons Infected with the Human Immunodeficiency Virus. In: Niederman MS, Sarosi G, Glassroth J (eds). *Respiratory Infections: A Scientific Basis for Management*. Philadelphia, PA: W.B. Saunders Company. 1994.
4. Dohn MN, Frame PT. Clinical Manifestations of *Pneumocystis carinii* Pneumonia in Adults. In Walzer PD (ed). *Pneumocystis carinii*. New York: Marcel Dekker, Inc. 1994.
5. Baughman RP, Dohn MN. Chapter 3. Immunocompromised Patients. In: Baughman RP (ed). *Bronchoalveolar Lavage*. St. Louis, MO: Mosby-Year Book, Inc. 1991.

SELECTED LETTERS & OTHER SOLICITED PUBLICATIONS

1. Dohn MN, Dohn AL. Acute unscheduled care [letter]. *Ann Int Med* 2013. In press.
2. Dohn MN, Dohn AL. Short-term Medical Missions: Some Quality of Care Issues. *Crossnetwork Journal*. November 2005. 1(1):31-45 (Available: <http://healthcaremissions.org/Crossnetworkjournal.html>) [Last access 27 August 2013].
3. Dohn MN, Dohn AL. New directions for medical ministries. *Misionero*, Spring Edition. Ambridge, PA: The South American Missionary Society. 1998.
4. Dohn MN, Borden T. *Recommended Procedure for Sending Missionaries – A manual for Parish use*. Cincinnati: Episcopal Diocese of Southern Ohio. 1998.
5. Baughman RP, Keely SP, Dohn MN, Stringer JR. The use of genetic markers to characterize transmission of *Pneumocystis carinii*. *AIDS Patients Care and STD's* 1997; 11:1131-1138.
6. Baughman RP, Dohn MN. Increased *Pneumocystis carinii* recovery from the upper lobes in *Pneumocystis pneumonia* [letter]. *Am J Respir Crit Care Med* 1995; 151:253-254.
7. Dohn MN, Gathe JC Jr, Haghghat DP. Atovaquone for *Pneumocystis carinii pneumonia* [letter]. *Ann Intern Med* 1995; 122:314-315.

ABSTRACTS (Selected from 28 abstracts)

- Dohn MN, Dohn AL, Reyes L. Housing conditions and survival of people with HIV infection in the Dominican Republic. American Society of Tropical Medicine and Hygiene. Annual Meeting, 4-8 Nov 2007, Philadelphia, PA, USA. *Am J Trop Med Hygiene* 2007; 77(5, Supplement): S40-S41.
- Montgomery L, Dohn M, Dohn A, and Holshausen K. Circulating medication, second opinions, and quality of life: An empirical assessment of short-term medical missions.

Annual Meeting of the American Anthropological Association. November 2006, San Jose, CA, USA.

- Dohn MN, Finkelstein DM, van der Horst C, Stamenovic E, Frame PT, Bozzette SA for the AIDS Clinical Trials Group. Long-term Aerosol Pentamidine Prophylaxis and Pulmonary Function. Infectious Diseases Society of America 35th Annual Meeting, September 15, 1997. Poster Presentation.
- Dohn MN, Baughman RP, Keeton DA. Interleukin-8 and neutrophilia in pneumocystis pneumonia. Presented at American Thoracic Society International Conference, May 22-25, 1994, Boston, MA, USA; Mini-Symposium on Immune Mechanisms in *Pneumocystis carinii* Pneumonia. Am J Respir Crit Care Med 1994; 149:A290.
- Dohn MN, Baughman RP, Frame PT. Pneumocystis cluster ratios in evaluating drug therapy for Pneumocystis pneumonia. Am Rev Respir Dis 1991; 143:A712.
- Dohn MN, Swank HC. Longitudinal study of spirometric pulmonary function tests in voice students. Am Rev Respir Dis 1990; 141 (World Conference on Lung Health Supplement):A715
- Dohn MN, Baughman RP. Comparison of methylene blue, potassium, and albumin as markers in bronchoalveolar lavage. Presented at the International Conference on Bronchoalveolar Lavage, National Institutes of Health, Columbia, MD, USA. May 11-16, 1984.